Evidence map›Paper›PMID 38069209›Full record

ArticleInternational journal of molecular sciences2023

Expression of Tissue Factor and Platelet/Leukocyte Markers on Extracellular Vesicles Reflect Platelet-Leukocyte Interaction in Severe COVID-19.

Tanja Eichhorn, René Weiss, Silke Huber, Marie Ebeyer-Masotta, Marwa Mostageer, Robert Emprechtinger, Ludwig Knabl, Ludwig Knabl, Reinhard Würzner, Viktoria Weber

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 7 citations in OpenAlex.

  1. Haemorrhage, hypercoagulability and ischaemia: Evolution of brain injury after aneurysmal subarachnoid haemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tanja EichhornCenter for Biomedical Technology, Department for Biomedical Research, University for Continuing Education Krems, 3500 Krems, Austria.ORCID 0000-0003-4158-026X
René WeissCenter for Biomedical Technology, Department for Biomedical Research, University for Continuing Education Krems, 3500 Krems, Austria.ORCID 0000-0003-0715-0493
Silke HuberInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-7021-1845
Marie Ebeyer-MasottaCenter for Biomedical Technology, Department for Biomedical Research, University for Continuing Education Krems, 3500 Krems, Austria.ORCID 0000-0002-2292-7312
Marwa MostageerCenter for Biomedical Technology, Department for Biomedical Research, University for Continuing Education Krems, 3500 Krems, Austria.
Robert EmprechtingerFaculty of Health and Medicine, University for Continuing Education Krems, 3500 Krems, Austria.
Ludwig KnablDepartment of Internal Medicine, Hospital St. Vinzenz, 6511 Zams, Austria.
Ludwig KnablTyrolPath, 6511 Zams, Austria.
Reinhard WürznerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0001-6804-442X
Viktoria WeberCenter for Biomedical Technology, Department for Biomedical Research, University for Continuing Education Krems, 3500 Krems, Austria.ORCID 0000-0002-3963-9077
Universität für Weiterbildung Krems · ATInnsbruck Medical University · ATTyrolit (Austria) · AT

Funding

Lower Austrian Society for Research Funding (GFF) K3-F-744/005-2019Technology Fund of Lower Austria WST3-F-5030664/032-2022
6 · The paper itself

Abstract

Severe COVID-19 is frequently associated with thromboembolic complications. Increased platelet activation and platelet-leukocyte aggregate formation can amplify thrombotic responses by inducing tissue factor (TF) expression on leukocytes. Here, we characterized TF-positive extracellular vesicles (EVs) and their cellular origin in 12 patients suffering from severe COVID-19 (time course, 134 samples overall) and 25 healthy controls. EVs exposing phosphatidylserine (PS) were characterized by flow cytometry. Their cellular origin was determined by staining with anti-CD41, anti-CD45, anti-CD235a, and anti-CD105 as platelet, leukocyte, red blood cell, and endothelial markers. We further investigated the association of EVs with TF, platelet factor 4 (PF4), C-reactive protein (CRP), and high mobility group box-1 protein (HMGB-1). COVID-19 patients showed higher levels of PS-exposing EVs compared to controls. The majority of these EVs originated from platelets. A higher amount of EVs in patient samples was associated with CRP, HMGB-1, PF4, and TF as compared to EVs from healthy donors. In COVID-19 samples, 16.5% of all CD41

Indexed as

COVID-19Extracellular VesiclesBlood PlateletsHMGB ProteinsHumansLeukocytesThromboplastinF3 protein, humanHMGB ProteinsThromboplastinCOVID-19extracellular vesiclesimmunothrombosisplatelet–leukocyte aggregatestissue factor

Identifiers

PMID38069209
PMCPMC10707108
OpenAlexW4389080685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.